ADAMTS13, recombinant-krhn 500 UNT Injection [Adzynma] — RxCUI 2670313
RxNorm drug concept · Semantic branded drug
RxCUI 2670313
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
2 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2670313
Official nameADAMTS13, recombinant-krhn 500 UNT Injection [Adzynma]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asAdzynma 500 UNT Injection
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)59 prescriptions · 3 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How ADAMTS13, recombinant-krhn 500 UNT Injection [Ad... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
ADAMTS13, recombinant-krhn 500 UNT Injection [Adzynma]
RxCUI 2670313 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
ADAMTS13, recombinant
2670285IN -
ADAMTS13, recombinant-krhn
2670286PIN
-
ADAMTS13, recombinant
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Adzynma
2670294BN
-
Adzynma
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
ADAMTS13, recombinant Injection
2670289SCDF -
ADAMTS13, recombinant-krhn Injection
2670291SCDFP -
ADAMTS13, recombinant Injectable Product
2670288SCDG -
ADAMTS13, recombinant-krhn Injectable Product
2670290SCDGP -
ADAMTS13, recombinant Injection [Adzynma]
2670297SBDF -
ADAMTS13, recombinant-krhn Injection [Adzynma]
2670298SBDFP -
Adzynma Injectable Product
2670296SBDG -
Injection
1649574DF - +1 more in this family
-
ADAMTS13, recombinant Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
ADAMTS13, recombinant-krhn 500 UNT Injection
2670311SCD -
ADAMTS13, recombinant-krhn 500 UNT
2670310SCDC -
ADAMTS13, recombinant-krhn 500 UNT [Adzynma]
2670312SBDC
-
ADAMTS13, recombinant-krhn 500 UNT Injection
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
ADAMTS13, recombinant-krhn 500 UNT Injection
SCD · 2670311 -
ADAMTS13, recombinant-krhn 500 UNT
SCDC · 2670310 -
ADAMTS13, recombinant Injection
SCDF · 2670289 -
ADAMTS13, recombinant-krhn Injection
SCDFP · 2670291 -
ADAMTS13, recombinant Injectable Product
SCDG · 2670288 -
ADAMTS13, recombinant-krhn Injectable Product
SCDGP · 2670290
Brand-Name Concepts
-
ADAMTS13, recombinant-krhn 500 UNT [Adzynma]
SBDC · 2670312 -
ADAMTS13, recombinant Injection [Adzynma]
SBDF · 2670297 -
ADAMTS13, recombinant-krhn Injection [Adzynma]
SBDFP · 2670298 -
Adzynma Injectable Product
SBDG · 2670296 -
Adzynma
BN · 2670294
📦 FDA Products & Package NDCs
2 products · 2 package NDCs
2 package NDCs map to RxCUI 2670313 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 64764-0140-05 | 1 KIT in 1 CARTON (64764-140-05) * 500 [iU] in 1 VIAL, SIN... | ADZYNMA | TAKEDA PHARMACEUTICALS AMERICA, INC. | 2023-11-09 |
| 64764-0145-05 | 1 KIT in 1 CARTON (64764-145-05) * 1500 [iU] in 1 VIAL, SI... | ADZYNMA | TAKEDA PHARMACEUTICALS AMERICA, INC. | 2023-11-09 |
Observed labelers:
TAKEDA PHARMACEUTICALS AMERICA, INC. (2)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J7171 | Inj, adzynma, 10 iu | 2 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.